Acute Leukemia

March 8, 2009

Older AML Patients Do Not Benefit From More Therapy

Charles H. Weaver, MD
March 8, 2009

Long-Term Study Shows Safety of Neupogen® in AML Treatment

Charles H. Weaver, MD
March 8, 2009

Expression of Genes Associated with Outcomes in Pediatric (ALL)

Charles H. Weaver, MD
March 8, 2009

CNS Recurrence of Childhood ALL May May Require More Aggressive Therapy

Charles H. Weaver, MD
March 8, 2009

Treatment w/ Reduced Intensity Allogeneic Stem Cell May Benefit Patients w/ AML

Charles H. Weaver, MD
March 8, 2009

Survival of Pediatric ALL Continues to Improve

Charles H. Weaver, MD
March 8, 2009

Older Age Doesn’t Affect in Patients with AML – MDS Who Undergo Mini-transplants

Charles H. Weaver, MD
March 8, 2009

KIT Mutations Associated with Poor Prognosis in Children with AML

Charles H. Weaver, MD
March 8, 2009

Tests May Improve Management of Patients with AML

Charles H. Weaver, MD
March 8, 2009

Patients with newly diagnosed acute myelogenous leukemia treated with autologous

Charles H. Weaver, MD
March 8, 2009

Genetic Differences Associated with Outcomes in Acute Myeloid Leukemia

Charles H. Weaver, MD
March 8, 2009

Oncaspar® Approved for Initial Treatment of Acute Lymphocytic Leukemia

Charles H. Weaver, MD